Key Insights

Highlights

Success Rate

86% trial completion

Published Results

28 trials with published results (21%)

Research Maturity

84 completed trials (62% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

10.4%

14 terminated out of 135 trials

Success Rate

85.7%

-0.8% vs benchmark

Late-Stage Pipeline

12%

16 trials in Phase 3/4

Results Transparency

33%

28 of 84 completed with results

Key Signals

28 with results86% success14 terminated

Data Visualizations

Phase Distribution

90Total
Not Applicable (20)
Early P 1 (3)
P 1 (17)
P 2 (34)
P 3 (6)
P 4 (10)

Trial Status

Completed84
Unknown14
Terminated14
Recruiting9
Active Not Recruiting7
Not Yet Recruiting5

Trial Success Rate

85.7%

Benchmark: 86.5%

Based on 84 completed trials

Clinical Trials (135)

Showing 20 of 20 trials
NCT07725263RecruitingPrimary

Low-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic Children

NCT07064941Not ApplicableActive Not RecruitingPrimary

Effect of Exercise on Body Composition and Bone Health in Patients With Thalassemia

NCT07698080Phase 2Not Yet Recruiting

Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploidentical Hematopoietic Stem Cell Transplantation

NCT04398628Recruiting

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

NCT02386800Phase 4Active Not Recruiting

CINC424A2X01B Rollover Protocol

NCT05356195Phase 3Active Not Recruiting

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

NCT07673302Not ApplicableNot Yet RecruitingPrimary

Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta Thalassemia

NCT06609226Phase 3Recruiting

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

NCT05736419Phase 2Recruiting

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT07579949Phase 2Not Yet RecruitingPrimary

A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT)

NCT03692052Phase 2Active Not RecruitingPrimary

A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia

NCT04208529Phase 3Enrolling By Invitation

A Long-term Follow-up Study in Participants Who Received CTX001

NCT05477563Phase 3Recruiting

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

NCT01758042Not ApplicableCompleted

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

NCT03249831Phase 1Active Not Recruiting

A Blood Stem Cell Transplant for Sickle Cell Disease

NCT05508932Recruiting

Atrial Fibrillation in Beta-Thalassemia

NCT06313398Early Phase 1Recruiting

Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling

NCT01911871CompletedPrimary

Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations

NCT07352878Not Yet RecruitingPrimary

Evaluation of the Quality of Life in Patients With Chronic Iron Overload Due to Hemoglobinopathies in Greece.

NCT07023029Phase 1Completed

A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants

Scroll to load more

Research Network

Activity Timeline